NanoBase™ Rx is a pharmacy compounding excipient that combines a tri-domain nano-colloidal Architecture with a lyotropic liquid crystal matrix. Engineered at Pensive Beauty Labs. The three engineered nano-domains (lipophilic, hydrophilic, interfacial bridging) are designed to be organized within a biomimetic lamellar and bicontinuous cubic liquid crystal phase structure that matches the native liquid crystalline lamellar organization of stratum corneum intercellular lipids. Lamellar and cubic phase organization is a design target pending small angle scattering confirmation. Excipient only. No API supplied.

Regulatory framework for sub-micron cosmetic formulas in 2026. EU Cosmetics Regulation 1223/2009 nano notification, FDA voluntary nano guidance, and ISO 29701 and 80004 standards relevant to brands building on NanoBase™, the tri-domain nano-colloidal Architecture engineered by Pensive Beauty® Nanoscience Labs.

Head-to-head technical comparison of three dominant nano-carrier architectures for cosmeceutical delivery: nanoemulsions (40 to 200 nm droplets), nanoliposomes (phospholipid bilayer vesicles), and nanomicelles (5 to 100 nm surfactant aggregates). Loading capacity, stability, stratum corneum penetration pathways, and why NanoBase™ tri-domain architecture from Pensive Beauty Labs outperforms single-class carriers.